A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

Ma Cynthia X.; Luo Jingqin; Naughton Michael; Ademuyiwa Foluso; Suresh Rama; Griffith Malachi; Griffith Obi L.; Skidmore Zachary L.; Spies Nicholas C.; Ramu Avinash; Trani Lee; Pluard Timothy; Nagaraj Gayathri; Thomas Shana; Guo Zhanfang; Hoog Jeremy; Han Jing; Mardis Elaine; Lockhart Craig; Ellis Matthew J.

首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

【24h】

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

机译：绝经后妇女雌激素受体阳性转移性乳腺癌BKM120（Buparlisib）与氟维西坦合用的I期试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose: This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive (ER+) breast cancer.

机译：目的：进行该试验以确定口服泛I类PI3K抑制剂buparlisib的最大耐受剂量（MTD）和初步疗效，该药物对转移性雌激素受体阳性（ER +）的绝经后妇女具有氟司韦特。

著录项

来源
《Clinical cancer research: an official journal of the American Association for Cancer Research 》 |2016年第7期| 共9页
作者
Ma Cynthia X.; Luo Jingqin; Naughton Michael; Ademuyiwa Foluso; Suresh Rama; Griffith Malachi; Griffith Obi L.; Skidmore Zachary L.; Spies Nicholas C.; Ramu Avinash; Trani Lee; Pluard Timothy; Nagaraj Gayathri; Thomas Shana; Guo Zhanfang; Hoog Jeremy; Han Jing; Mardis Elaine; Lockhart Craig; Ellis Matthew J.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer [J] . Ma Cynthia X., Luo Jingqin, Naughton Michael, Clinical cancer research: an official journal of the American Association for Cancer Research . 2016 ,第7期

机译：绝经后妇女雌激素受体阳性转移性乳腺癌BKM120（Buparlisib）与氟维西坦合用的I期试验
2. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 18, pg 904, 2017) [J] . Baselga J., Im S-A, Iwata H. Nature reviews neuroscience . 2019 ,第2期

机译：Buparlisib Plus FulvaStrant与安慰剂加上氟斯特语，激素受体阳性，Her2阴性，晚期乳腺癌（Belle-2）：A随机，双盲，安慰剂控制，第3阶段试验（Vol 18，PG 904,2017 的）
3. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J] . Baselga Jose, Im Seock-Ah, Iwata Hiroji, The lancet oncology . 2017 ,第7期

机译：Buparlisib Plus FulvaStrant与安慰剂加上氟氯雌激素，激素受体阳性，Her2阴性，晚期乳腺癌（Belle-2）：一个随机，双盲，安慰剂控制，第3期试验
4. Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive Assays [C] . Frederick L. Baehner International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：雌激素受体阳性乳腺癌：传统预测，分子病理：新的乳腺癌分类和21世纪个性化预测和预测测定
5. The SERM, arzoxifene, and the rexinoid, LG100268, cooperate to prevent estrogen receptor-positive and -negative breast cancer as well as colon cancer. [D] . Rendi, Mara H. 2004

机译：SERM，arzoxifene和类维生素LG100268共同预防雌激素受体阳性和阴性乳腺癌以及结肠癌。
6. A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer [O] . Cynthia X. Ma, Jingqin Luo, Michael Naughton, -1

机译：BKM120（Buparlisib）与氟维司群联合在绝经后女性雌激素受体阳性转移性乳腺癌中的1期试验
7. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial [O] . José Baselga, Seock-Ah Im, Hiroji Iwata, 2017

机译：Buparlisib Plus FulvaStrant与安慰剂加上氟斯特语，激素受体阳性，Her2阴性，晚期乳腺癌（Belle-2）：A随机，双盲，安慰剂控制，第3期试验

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer

摘要

著录项

相似文献

相关主题

期刊订阅